Cargando…

Clinical manufacturing of CAR T cells: foundation of a promising therapy

The treatment of cancer patients with autologous T cells expressing a chimeric antigen receptor (CAR) is one of the most promising adoptive cellular therapy approaches. Reproducible manufacturing of high-quality, clinical-grade CAR-T cell products is a prerequisite for the wide application of this t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiuyan, Rivière, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909095/ https://www.ncbi.nlm.nih.gov/pubmed/27347557 http://dx.doi.org/10.1038/mto.2016.15

Ejemplares similares

Genetic Engineering and Manufacturing of Hematopoietic Stem Cells
por: Wang, Xiuyan, et al.
Publicado: (2017)

How do CARs work?: Early insights from recent clinical studies targeting CD19
por: Davila, Marco L., et al.
Publicado: (2012)

Global Manufacturing of CAR T Cell Therapy
por: Levine, Bruce L., et al.
Publicado: (2016)

CAR-T cell therapy for hematological malignancies: History, status and promise
por: Wang, Chao, et al.
Publicado: (2023)

CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
por: Zhang, Xi-Wen, et al.
Publicado: (2023)

CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy
por: Pagotto, Sara, et al.
Publicado: (2023)

CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
por: Sabbah, Mohamad, et al.
Publicado: (2022)

CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
por: Hovhannisyan, Lusine, et al.
Publicado: (2023)

Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
por: Aparicio, Cristina, et al.
Publicado: (2021)

CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy
por: Hadiloo, Kaveh, et al.
Publicado: (2023)

Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
por: Zhang, Meng, et al.
Publicado: (2021)

Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
por: Hamieh, Mohamad, et al.
Publicado: (2023)

CAR-NK cells: A promising cellular immunotherapy for cancer
por: Xie, Guozhu, et al.
Publicado: (2020)

CAR‐NK cell in cancer immunotherapy; A promising frontier
por: Marofi, Faroogh, et al.
Publicado: (2021)

Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
por: Torti, Davide, et al.
Publicado: (2011)

Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials
por: Tyagarajan, Seshu, et al.
Publicado: (2019)

CAR-T cell therapy for lung cancer: a promising but challenging future
por: Zhong, Shupeng, et al.
Publicado: (2020)

Impact of Manufacturing Procedures on CAR T Cell Functionality
por: Watanabe, Norihiro, et al.
Publicado: (2022)

Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing
por: Wang, Xiuyan, et al.
Publicado: (2021)

The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology
por: Mohseni, Yasmin R., et al.
Publicado: (2020)

Rapid manufacturing of non-activated potent CAR T cells
por: Ghassemi, Saba, et al.
Publicado: (2022)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Potential solutions for manufacture of CAR T cells in cancer immunotherapy
por: Blache, Ulrich, et al.
Publicado: (2022)

Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
por: Balke-Want, Hyatt, et al.
Publicado: (2023)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications
por: Silveira, Caio Raony Farina, et al.
Publicado: (2022)

Infectious complications of CAR T-cell therapy: a clinical update
por: Stewart, Adam G., et al.
Publicado: (2021)

CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
por: Marofi, Faroogh, et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Clinical development of CAR T cell therapy in China: 2020 update
por: Wei, Jianshu, et al.
Publicado: (2020)

Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy
por: Vedvyas, Yogindra, et al.
Publicado: (2019)

New development in CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2017)

Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions
por: Dong, Zhenyuan, et al.
Publicado: (2020)

Additive Manufacturing of Polymer Materials: Progress, Promise and Challenges
por: Saleh Alghamdi, Saad, et al.
Publicado: (2021)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Donor T cells for CAR T cell therapy
por: Tang, Tiffany C. Y., et al.
Publicado: (2022)

Steering CAR T cell epigenetic programs by tweaking manufacturing protocol
por: Dukes, Meghan W., et al.
Publicado: (2023)

Get Off on the Right Foot: How to Plan an Efficient Leukocytapheresis to Collect T Cells for CAR T-Cell Manufacturing
por: Piñeyroa, Juan A., et al.
Publicado: (2022)

Applying a clinical lens to animal models of CAR-T cell therapies
por: Duncan, Brynn B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dn1cv3vajmg8m0ht7m78hlshri